EyePoint closes upsized $230M public offering for wet AMD Phase 3 trials

EyePoint, Inc.

Closed upsized public offering of 13,529,411 shares at $17.00/share, raising ~$230M gross.
Underwriters fully exercised option for 1,764,705 additional shares.
Net proceeds to fund EYP-1901 wet AMD Phase 3 pivotal trials and early pipeline.
Joint book-runners: J.P. Morgan, TD Cowen, Guggenheim; Cantor as additional book-runner.
Offerings were upsized from $175M initial to $200M priced, then $230M at close.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.